Lonafarnib Sarasar Active substance LonafarnibDomain Metabolism and EndocrinologyReason of inclusion in Horizonscan Geneesmiddelen New medicine (specialité)Main indication Metabolic diseasesExtended indication Hutchinson-Gilford Progeria Syndrome and Progeroid Laminopathies. 1. Product Proprietary name SarasarManufacturer Eiger BioMechanism of action Virus inhibitorRoute of administration OralTherapeutical formulation CapsuleBudgetting framework Extramural (GVS) 2. Registration Registration route Centralised (EMA)Type of trajectory Accelerated assessmentSubmission date April 2020Expected Registration December 2020Orphan drug YesRegistration phase Registration application pending 3. Therapeutic value Therapeutic value No judgementDuration of treatment Not foundReferences NCT02579044 4. Expected patient volume per year There is currently nothing known about the expected patient volume. 5. Expected cost per patient per year There is currently nothing known about the expected cost. 6. Potential total cost per year There is currently nothing known about the possible total cost. 7. Off label use There is currently nothing known about off label use. 8. Indication extension There is currently nothing known about indication extensions. 9. Other information There is currently no futher information available.